HIV/AIDS drugs mean people can live normal lives provided they are adherent to antiretroviral therapy. But treatment comes at a cost, and in the case of a number of African countries with high HIV prevalences this is often greater than the current per capita health expenditure.read full post
Kenya’s HIV/AIDS 2015 conference, Maisha 2015 (meaning life in Swahili), in which I gave a Keynote Address, highlighted the knowledge and advocacy resources that have been mobilized by the country to fight the HIV pandemic.read full post
RethinkHIV is a consortium of senior researchers from London School of Hygiene & Tropical Medicine, Imperial College London, Harvard School of Public Health, Centre for the Study of African Economies and Blavatnik School of Government at Oxford University.
The consortium will evaluate new evidence related to the costs, benefits, effects, fiscal implications, and developmental impacts of HIV interventions in sub-Saharan Africa, in order to maximise contributions to the fight against HIV there.
The aim of RethinkHIV is to find ways of creating, optimising, and sustaining fiscal space for domestic HIV investment, as well as exploring long-term, sustainable national and international financing mechanisms. RethinkHIV is funded by RUSH Foundation.